Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2010 - 2026)

Neurocrine Biosciences has reported Change in Acquisitions & Divestments for 17 years, with the latest figure at $259.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 13.05% year-over-year to $259.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 6.19% YoY), and the FY2025 full-year result was $1.1 billion, up 12.6% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $259.2 million, down from $267.7 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $298.6 million in Q2 2025, with the low at $71.2 million in Q3 2022.
• Historically, Change in Acquisitions & Divestments has averaged $223.5 million across 5 years, with a median of $250.8 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments tumbled 55.42% — and 2023, when it soared 283.43%.
• Neurocrine Biosciences' Change in Acquisitions & Divestments stood at $162.2 million in 2022, then jumped by 79.28% to $290.8 million in 2023, then slipped by 13.76% to $250.8 million in 2024, then increased by 6.74% to $267.7 million in 2025, then slipped by 3.18% to $259.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $259.2 million (Q1 2026), $267.7 million (Q4 2025), and $225.0 million (Q3 2025), per Business Quant data.